<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320408</url>
  </required_header>
  <id_info>
    <org_study_id>NL59991.018.17</org_study_id>
    <secondary_id>Biobank Pearl AAA</secondary_id>
    <nct_id>NCT03320408</nct_id>
  </id_info>
  <brief_title>Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers</brief_title>
  <acronym>PARIS</acronym>
  <official_title>Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers (PARIS Study) &amp; Biobank Pearl AAA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ron Balm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parelsnoer Institute the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First aim: PARIS study&#xD;
&#xD;
      The main aim of the current study is to determine the association between abdominal aortic&#xD;
      aneurysm (AAA) progression and the evolution of proteases and cytokines levels.To achieve&#xD;
      this aim, we will prospectively collect blood, aortic tissue, patient data, and imaging data.&#xD;
      Aortic tissue will only be obtained when patients undergo conventional open repair. The other&#xD;
      biomaterials will be collected during regular patient follow-up visits, with a maximum&#xD;
      frequency of once per year.&#xD;
&#xD;
      Second aim: Pearl AAA biobank&#xD;
&#xD;
      For future research purposes, a new biobanking infrastructure will be created to collect and&#xD;
      store additional blood and urine samples in a biobank. This biobank will be embedded within&#xD;
      the infrastructure of the 'Parelsnoer Institute' (PSI) and will be called Pearl AAA. The&#xD;
      Pearl AAA will be established in the extension of the PARIS study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PARIS study aims to determine the correlation between AAA progression (growth or rupture)&#xD;
      and the evolution of serum levels of proteases and cytokines over time. A repeated measures&#xD;
      analysis will be done to use all longitudinal data available.&#xD;
&#xD;
      The Pearl AAA biobank will be established to enable the PARIS study, but also aims to&#xD;
      facilitate future research. Such future research should fall under the scientific aims of the&#xD;
      Pearl AAA, which are:&#xD;
&#xD;
        -  To gain insight in the pathogenesis of AAA&#xD;
&#xD;
        -  To gain more knowledge in the rupture risk of AAA&#xD;
&#xD;
        -  To evaluate and potentially improve treatment of AAA&#xD;
&#xD;
      The 'Parelsnoer Institute' will facilitate the biobank Pearl AAA with certain aspects such&#xD;
      as, but not limited to the following:&#xD;
&#xD;
        -  Standardized operating procedures for the collection and storage of the biosamples&#xD;
           across all participating hospitals&#xD;
&#xD;
        -  Information architect to establish a data dictionary in which all variables are defined&#xD;
&#xD;
        -  Standardized procedures for coding of patient data before storage&#xD;
&#xD;
        -  Standardized digital infrastructure to enhance storage of patient data and imaging data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">October 4, 2032</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2032</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>AAA growth</measure>
    <time_frame>Up to 10 years of follow-up</time_frame>
    <description>Growth of abdominal aortic aneurysm, measured on imaging made for clinical purposes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AAA rupture</measure>
    <time_frame>Up to 10 years of follow-up</time_frame>
    <description>Rupture of an abdominal aortic aneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Up to 10 years of follow-up</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of serum levels of proteases</measure>
    <time_frame>a maximum of 1 measurement annually up to 10 years of follow-up</time_frame>
    <description>Repeated measurements analysis of serum levels of proteases in cohort of asymptomatic AAAs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of serum levels of cytokines</measure>
    <time_frame>a maximum of 1 measurement annually up to 10 years of follow-up</time_frame>
    <description>Repeated measurements analysis of serum levels of cytokines in cohort of asymptomatic AAAs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protease levels in aortic tissue</measure>
    <time_frame>If open AAA repair is performed and aortic tissue is collected, protease levels will then be measured. This is a one-time measurement.</time_frame>
    <description>Protease levels in aortic tissue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine levels in aortic tissue</measure>
    <time_frame>If open AAA repair is performed and aortic tissue is collected, cytokine levels will then be measured. This is a one-time measurement.</time_frame>
    <description>Cytokine levels in aortic tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of complications after AAA repair</measure>
    <time_frame>Will be measured up to 10 years after AAA repair is performed</time_frame>
    <description>Type of complications using methodology from the Dutch committee of the &quot;Nederlandse Vereniging voor Heelkunde,&quot; named the &quot;Landelijke Heelkunde Complicatie Registratie&quot; as found on www.lhcr.nl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications after AAA repair</measure>
    <time_frame>Will be measured up to 10 years after AAA repair is performed</time_frame>
    <description>Number of complications after abdominal aortic aneurysm repair</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <condition>Abdominal Aortic Aneurysm, Ruptured</condition>
  <arm_group>
    <arm_group_label>Asymptomatic AAA</arm_group_label>
    <description>These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute AAA</arm_group_label>
    <description>These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repaired AAA</arm_group_label>
    <description>These patients are included while they already had had AAA repair (both elective and emergency repair).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Three types of biospecimens will be collected, depending on the clincial stage of the&#xD;
      abdominal aortic aneurysm.&#xD;
&#xD;
      Blood:&#xD;
&#xD;
      EDTA plasma; Serum; Citrate plasma; EDTA for DNA; PAXgene for RNA.&#xD;
&#xD;
      Urine.&#xD;
&#xD;
      Aneurysm tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients with an abdominal aortic aneurysm who present themselves in the&#xD;
        participating hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participant (18 years or older)&#xD;
&#xD;
          -  Participant has an AAA or has previously been treated for an AAA&#xD;
&#xD;
          -  Adequate comprehension of the Dutch language to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient who is decisionally impaired. The only exception to this are the patients&#xD;
             who are decisionally impaired due to the effects of an acute AAA. This particular&#xD;
             group is eligible for which a separate recruitment and consent procedure exists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Balm, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Tedjawirja, MD</last_name>
    <phone>+31205663405</phone>
    <email>v.n.tedjawirja@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Tedjawirja, MD</last_name>
      <phone>+31205663405</phone>
      <email>v.n.tedjawirja@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>K Yeung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center (LUMC)</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Tedjawirja, MD</last_name>
      <phone>+31205663405</phone>
      <email>v.n.tedjawirja@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>J F Hamming, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Tedjawirja, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ron Balm, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Ron Balm</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>biobank</keyword>
  <keyword>pathogenesis</keyword>
  <keyword>Aortic Aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Aneurysm, Ruptured</mesh_term>
    <mesh_term>Aortic Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can initiate the procedure to request IPD for research that falls within the scientific scope of the biobank Pearl AAA.</ipd_description>
    <ipd_time_frame>Depending on the specific study protocols that are submitted to the biobank Pearl AAA</ipd_time_frame>
    <ipd_access_criteria>Procedural criteria can be attained by contacting the researchers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

